The Large Underground Xenon detector is being used to seek dark matter.
Image: Lawrence Berkeley National Lab
Stem-cell trials
Landmark results from an early-stage clinical trial using human embryonic stem cells (hESCs) should appear this year. Biotechnology firm Advanced Cell Technology of Santa Monica, California, is injecting hESC-derived retinal cells into the eyes of around three dozen people with two forms of non-treatable degenerative blindness. It is the only company currently testing hESC therapies with U.S. Food and Drug Administration (FDA) approval, and it hopes that the agency will give it the green light to test stem cells induced from adult cells in patients this year.
Diagnostics controversy
The American Psychiatric Association will publish the fifth edition of its Diagnostic and Statistical Manual of Mental Disorders (DSM-5) in May, the first major update in 19 years to the standard reference guide for diagnosing mental illnesses. It will lead to controversial changes in clinical and research protocols, including restructured diagnoses for autism and major depression, although as a ‘living document’ the DSM-5 will see further revisions.
Climate assessment
Climate scientists have spent years preparing the fifth assessment report from the Intergovernmental Panel on Climate Change, its first update since 2007. Part of that report is due to appear in September: the conclusions of Working Group I, which summarizes the basic science of global warming. In the U.S., the Global Change Research Program’s second assessment will detail the national impacts of climate change.
The Big Bang’s glow
One of the stunning images of the year could be provided by the comet ISON, which will pass close to the Sun in November and could outshine the full Moon as its surface boils away into space. Just as spectacular will be the Planck space telescope’s map of the faint microwave afterglow from the Big Bang, which could even reveal ripples from gravitational waves generated during an initial period of cosmic ‘inflation’. In other missions, NASA’s LADEE spacecraft will orbit the Moon to study lunar dust; its MAVEN mission will launch to explore Mars’ upper atmosphere; and the Curiosity rover will continue to send back results from the red planet’s surface. Back on Earth, Chile’s massive 66-dish Atacama Large Millimeter/submillimeter Array will be completed.
Diet, microbes and cancer
Scientists increasingly suspect that our intestinal zoo of microbes might be the key link between diet and diseases such as cancer. A study last year connected a higher proportion of the bacterium Escherichia coli to colorectal cancer in mice with inflammatory bowel disease (J. C. Arthur et al. Science 338, 120–123; 2012). More studies this year will unpick the effect of diets on the gut microbiome and their implications for disease risk. Meanwhile, GlaxoSmithKline should find out whether the FDA approves its melanoma treatment trametinib, potentially the first in a new class of compound that inhibits a kinase signaling pathway regulating cell growth.
Particle seeking
After contradictory sightings of dark-matter particles from various underground experiments, the Large Underground Xenon detector at the Sanford Underground Research Facility in Lead, S.D., may this year boost or rule out some of the claims. The king of particle hunters—the Large Hadron Collider at CERN near Geneva—will shut down until 2015 for an upgrade to enable more powerful collisions, but physicists will continue to pore over the data collected so far for hints of supersymmetry.
The lower depths
See what we're tweeting about
3 Comments
Add CommentAn exciting year ahead on many fronts. The UK policy on publicly funded research should help to reduce dodgy claims & needs to be emulated. My greatest desire is to see integrity restored to the branches of science that have been adhering more closely to an agenda than honest unbiased research.
Reply | Report Abuse | Link to thisThis would be infinitely easier to achieve if we also had an honest press prepared to ask questions rather than glibly swallowing press releases.
Hear hear, Carlyle.
Reply | Report Abuse | Link to thisWe need journalists who understand science - if I were a biology student now (rather than three decades ago) I'd consider becoming an environmental journalist.
What we also need are politicians from a wide range of backgrounds, including politicians who understand science - in Britain we have almost no politicians with a background in science or engineering or almost any practical job, or a background with a wider perspective such as history.
We're all suffering because almost all we've got are politicians who studied economics or law and who then had a political office job.
We need adequate, secure funding for science research and teaching, and especially for environmental science - but many environmental subjects are under threat in many universities and research organisations.
Of course paying generic drug companies not to produce off patent drugs is a "combination in restraint of trade".
Reply | Report Abuse | Link to thisWhat could be more obvious? Not only did they collude, but the generic manufacturer is being paid off with the monopoly profits.